Get the Stockscreener App
0.2895
1.02%
-0.0032
IGC Pharma Inc stock is traded at $0.2895, with a volume of 426.17K.
It is down -1.02% in the last 24 hours and down -2.75% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.2927
Open:
$0.2973
24h Volume:
426.17K
Relative Volume:
0.55
Market Cap:
$26.92M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.1135
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
+2.55%
1M Performance:
-2.75%
6M Performance:
-4.23%
1Y Performance:
-15.44%
1-Day Range:
$0.2885
$0.2973
1-Week Range:
$0.275
$0.2973
52-Week Range:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2899 | 27.18M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - GuruFocus
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
This drug developer is switching its fiscal year to match your calendar - Stock Titan
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international markets2026 world cup usa national team round of 32 midfield engines high defensive line tactical prediction preview - Улправда
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
Small biotech secures cash to keep its Alzheimer's trial moving - Stock Titan
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
IGC Pharma Inc. (IGC) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
IGC Pharma (FRA:IGS1) EV-to-OCF : -4.65 (As of Dec. 21, 2025) - GuruFocus
How IGC Pharma Inc. stock responds to policy changesWeekly Trend Summary & Long-Term Capital Growth Strategies - Улправда
Will IGC Pharma Inc. stock outperform benchmarksInflation Watch & Verified Swing Trading Watchlists - Улправда
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - GuruFocus
IGC Pharma Secures U.S. Patent for Innovative Stuttering Treatme - GuruFocus
What makes IGC Pharma Inc. stock appealing to growth investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - DonanımHaber
How IGC Pharma Inc. stock benefits from strong dollarWeekly Trade Report & High Return Trade Opportunity Guides - DonanımHaber
Can IGC Pharma Inc. stock deliver strong Q4 earningsWeekly Investment Summary & Technical Buy Zone Confirmation - DonanımHaber
Why IGC Pharma Inc. stock remains stableJuly 2025 Selloffs & Low Risk Growth Stock Ideas - DonanımHaber
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsTrade Volume Report & Technical Pattern Alert System - Улправда
Aug Analyst Calls: How IGC Pharma Inc. (IGS1) stock expands through international markets2025 Pullback Review & Long-Term Growth Stock Strategies - Улправда
IGC Pharma Inc - Reuters
IGC Pharma comments on potential reclassification of cannabis - MSN
IGC Pharma Increases Authorized Shares to 600 Million - The Globe and Mail
IGC Pharma Positions as a Singular Beneficiary of Emerging Feder - GuruFocus
IGC Pharma (IGC) Advances in FDA-regulated Cannabinoid Drug Deve - GuruFocus
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cann - pharmiweb.com
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Weatherford Democrat
IGC Pharma Inc IGC’s stock price falss traction on Thursday - uspostnews.com
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the - Big News Network.com
IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation - Nasdaq
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
Ascendiant Capital Maintains IGC Pharma (IGC) Buy Recommendation - Nasdaq
IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 C - GuruFocus
IGC Achieves Significant Enrollment Progress in Phase 2 Alzheimer's Trial - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - pharmiweb.com
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):